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ABSTRACT
Despite advances in insulin therapies, patients
with type 1 diabetes (T1DM) have a shorter life
span due to hyperglycaemia-induced vascular
disease and hypoglycaemic complications sec-
ondary to insulin therapy. Restricting therapy
for T1DM to insulin replacement is perhaps an
over-simplistic approach, and we focus in this
work on reviewing the role of adjuvant therapy
in this population. Current data suggest that
adding metformin to insulin therapy in T1DM
temporarily lowers HbA1c and reduces weight
and insulin requirements, but this treatment
fails to show a longer-term glycaemic benefit.
Agents in the sodium glucose co-transporter-2
inhibitor (SGLT-2) class demonstrate the great-
est promise in correcting hyperglycaemia, but
there are safety concerns in relation to the risk
of diabetic ketoacidosis. Glucagon-like peptide-
1 agonists (GLP-1) show a modest effect on
glycaemia, if any, but significantly reduce
weight, which may make them suitable for use
in overweight T1DM patients. Treatment with
pramlintide is not widely available worldwide,
although there is evidence to indicate that this
agent reduces both HbA1c and weight in T1DM.
A criticism of adjuvant studies is the heavy
reliance on HbA1c as the primary endpoint
while generally ignoring other glycaemic
parameters. Moreover, vascular risk markers and
measures of insulin resistance—important con-
siderations in individuals with a longer T1DM
duration—are yet to be fully investigated fol-
lowing adjuvant therapies. Finally, studies to
date have made the assumption that T1DM
patients are a homogeneous group of individu-
als who respond similarly to adjuvant therapies,
which is unlikely to be the case. Future longer-
term adjuvant studies investigating different
glycaemic parameters, surrogate vascular mark-
ers and harder clinical outcomes will refine our
understanding of the roles of such therapies in
various subgroups of T1DM patients.
Keywords: DPP-4 inhibitors; GLP-1 analogues;
Hypoglycaemia agents; Metformin; Pramlintide;
SGLT2 inhibitors; Type 1 diabetes (T1DM)
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INTRODUCTION
It has long been known that type 1 diabetes
mellitus (T1DM) is associated with an increased
incidence of adverse vascular events, and that
these cardiovascular events occur at a younger
age than in the nondiabetic population [1].
Despite advances in therapy, the rate of end
organ damage in T1DM remains high, and
mortality is significantly increased compared to
individuals without diabetes. The National
Institute for Health and Care Excellence (NICE)
in the United Kingdom recommends that
patients should aim to achieve a glycated hae-
moglobin (HbA1c) below 48 mmol/mol unless
they are troubled by recurrent hypoglycaemia,
in which case individualised targets should be
agreed on a patient-by-patient basis [2]. Simi-
larly, the American Diabetes Association rec-
ommends HbA1c\ 7% (53 mmol/mol) in
T1DM patients, with a lower level of 6.5%
(48 mmol/mol) in selected individuals [3]. The
current standard treatment predominantly
involves intensive insulin regimes that aim to
lower HbA1c in order to reduce the risk of
microvascular disease and limit long-term
macrovascular complications [4, 5].
A key aim in these patients is the reduction
of macrovascular events, but the relationship
between glycaemic control and vascular occlu-
sive disease is far more complex than initially
envisaged. The DCCT-EDIC trial has shown that
lowering HbA1c reduces the long-term risk of
myocardial infarction [6]. However, intensively
treating glycaemia predisposes to hypogly-
caemia, which in itself increases the risk of
vascular events [7]. Mechanisms for hypogly-
caemia-induced vascular damage include the
induction of an inflammatory and prothrom-
botic milieu due to low glucose levels [8]. To
further complicate matters, large fluctuations in
glucose control, typically seen in individuals
with inadequate insulin dosing, are also
thought to be associated with vascular damage
through increased oxidative stress and an
enhanced inflammatory response [9]. Our
understanding of the mechanistic pathways
linking glucose variability with increased car-
diovascular risk is incomplete and causality has
yet to be fully proven, but the evidence behind
this being a contributory factor in the devel-
opment of cardiovascular disease (CVD) is
growing [10].
In addition to the detrimental effects of
hypoglycaemia, the weight gain associated with
insulin treatment predisposes to insulin resis-
tance, which promotes vascular damage
through the induction of endothelial dysfunc-
tion and predisposition to an inflammatory and
prothrombotic environment [11]. This explains
the failure of some HbA1c-focussed studies in
T1DM to demonstrate significant associations
between this glycaemic marker and adverse
vascular events, instead suggesting that insulin
resistance may play a stronger role in the
development of these complications [12, 13].
Weight gain has been implicated in
increased insulin resistance, and this is a well-
established mechanism underlying the patho-
genesis of type 2 diabetes mellitus (T2DM) [14].
Therefore, T1DM patients who are overweight
can develop insulin resistance, giving rise to the
‘double diabetes’ (DD) phenotype. The defini-
tion of DD is yet to be formalised and is cur-
rently used as a loose term to describe
overweight T1DM patients, particularly in the
presence of increased insulin requirements.
Previous work has shown that patients with
T1DM are particularly prone to weight gain,
with one large prospective study demonstrating
a sevenfold increase in the rate of obesity in
T1DM over a follow-up period of 18 years as
compared with the general population [15].
Other studies have confirmed the increased
prevalence of obesity in T1DM [16], raising the
question as to whether adjuvant medications
should be considered in these patients to reduce
weight irrespective of changes in markers of
glycaemic control. Moreover, evidence suggests
that overweight T1DM patients are at higher
risk of vascular complications compared with
their lean counterparts [17], further highlight-
ing the need for alternative, non-insulin-based
therapies in these individuals.
The current review assesses the role of adju-
vant non-insulin-based therapies in T1DM in
relation to improving glycaemia, controlling
weight and modulating the risk of vascular
complications of diabetes. We have conducted a
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PubMed search of articles using the terms ‘type
1 diabetes’ and ‘metformin’, ‘sodium glucose
co-transporter-2 inhibitors (SGLT2)’ (and each
member of this family), ‘glucagon like peptide-1
agonists (GLP-1)’ (and each member of this
family), ‘amylin’ (and ‘pramlintide’) and
‘dipeptidyl peptidae-4 inhibitors (DPP4)’ (and
each member of the family) up to June 2018,
and attempted to summarise the major trials for
each class.
This article is based on previously conducted
clinical trials and does not contain unpublished
work with human participants or animals per-
formed by any of the authors.
METFORMIN
Metformin, a biguanide agent, has been used for
the treatment of T2DM for over half a century.
Its exact mode of action is not entirely clear, but
it is believed to inhibit production of hepatic
glucose, reduce intestinal glucose absorption
and improve glucose uptake and utilisation
[18]. The use of metformin in T1DM has been
repeatedly suggested, with some studies—but
not all—showing improved glycaemic control,
assessed as a reduction in HbA1c.
One of the largest studies is the recent ran-
domised controlled REMOVAL trial, which
involved 428 T1DM patients. The study inves-
tigated the role of metformin in modulating
carotid intima media thickness (cIMT) in those
above the age of 40 years with multiple cardio-
vascular risk factors [19]. Metformin had no
significant effect on cIMT, although a decrease
in HbA1c 3 months after the introduction of
metformin (- 0.24%, p = 0.0001) was demon-
strated, which was not sustained at study end
(3 years). A much smaller trial involving 15
T1DM patients with an average body mass
index (BMI) of 31.3 kg/m2 reported a decrease in
HbA1c of 0.8% (p\ 0.005) after 16 weeks of
metformin treatment compared to placebo [20].
Similarly, a significant reduction in HbA1c of
(0.6%) (DCCT-aligned) was observed in a trial of
114 patients over 6 months compared to pla-
cebo (? 0.2%) (DCCT-aligned) (p\ 0.001) [21].
No significant difference in HbA1c was reported
in trials with durations of 24 weeks to 1 year,
involving 24–100 overweight patients with
HbA1c[ 7% [22–24]. Similarly, a recent meta-
analysis of 13 trials did not identify enough
evidence to suggest HbA1c is significantly low-
ered by adjuvant metformin [25].
While the effects of metformin on glycaemia
appear to be short term and unsustained, a
reduction in daily insulin dose has been repor-
ted in several trials when metformin was added
to standard therapy. In a 16-week trial involving
15 overweight patients, a significant decrease in
insulin dose by 10 units/day was reported [20].
Similarly, a 24-week trial involving 24 over-
weight patients reported a significant reduction
in daily insulin dose of 8.8 units/day [22].
Another larger trial with a duration of 1 year,
comprising 100 T1DM patients with poor gly-
caemic control (HbA1c[8.5%) and an average
BMI of 26.2 kg/m2, reported a decrease of 5.7
units/day in insulin dose compared with pla-
cebo [24]. Moreover, a trial of 114 patients over
6 months also identified a reduction of
0.04 units/kg compared to placebo (0.02 units/
kg, p = 0.004) [21]. Additional small trials
reported nonsignificant decreases in the total
daily insulin dose [23]. Taken together, these
data suggest a general reduction in insulin dose
after the introduction of metformin, but long-
term studies are lacking. REMOVAL was one of
the longest and largest studies of the use of
metformin in T1DM, and this showed an initial
reduction in total daily insulin requirement
which was not sustained at 3 years [19].
Multiple studies involving overweight
patients provide evidence of significant weight
loss associated with metformin use for up to
3 years [19, 21–24]. A recent meta-analysis of 13
trials identified the same outcome, with a
reduction in BMI of - 1.14 kg/m2 (- 2.05 to
- 0.24, p = 0.01) [25]. Others failed to corrobo-
rate these findings, although these were gener-
ally small studies conducted over 8–16 weeks
and involving no more than 24 patients each
[20, 26]. A recent retrospective study of 181
patients who were taking metformin or stan-
dard therapy found no significant difference in
weight over 10 years of follow-up [27]. Of note,
the groups were not evenly matched, with those
taking metformin having a significantly
increased BMI compared to those not taking
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metformin at study onset (29.8 vs 28.6 kg/m2;
p\0.01). Confounders such as diet and physi-
cal exercise were not included in analysis. The
retrospective design of the study and the fact
that the groups were not evenly matched at
study onset make it challenging to draw con-
clusions about the ability of metformin to
reduce weight in those with T1DM over longer
time periods.
Metformin is not known to cause hypogly-
caemia as it does not stimulate endogenous
insulin secretion; however, in insulin-treated
patients it can theoretically increase the risk of
low glucose levels [18]. A meta-analysis of 13
trials involving 1,183 patients identified an
increased hypoglycaemic risk with adjuvant
metformin (1.23, CI 1.00–1.52, p = 0.05) [25].
The REMOVAL trial involving 387 patients
reported 0.16 severe hypoglycaemic events per
patient per year, which was similar to the con-
trol arm [19]. Another trial uncovered 58 events
of severe hypoglycaemia in 49 patients over a
1-year period [24] in metformin-treated T1DM
patients, but this was not significantly different
from the placebo group (p = 0.261). Finally,
another trial identified no statistical difference
between 114 patients taking adjuvant met-
formin and the placebo group (p = 0.2) [21].
Overall, metformin reduces HbA1c initially,
but this effect does not appear to be sustained.
Also, metformin reduces daily insulin doses, but
again this reduction is not seen over longer
periods of follow-up. Metformin-related weight
loss is perhaps more sustained, but long-term
conclusive data are lacking. Metformin does not
appear to increase the rate of severe hypogly-
caemic events, although the role of this agent in
contributing to milder hypoglycaemia is
unclear and will require continuous glucose
monitoring studies.
A summary of the main studies of metformin
in T1DM is provided in Table 1.
SGLT2 INHIBITORS
Sodium glucose co-transporter type 2 mediates
the reabsorption of glucose in the renal tubule,
so inhibiting this co-transporter results in gly-
cosuria and reduces blood glucose levels [28].
Moreover, this is associated with weight loss
and reduced blood pressure, further helping
individuals with T2DM and the metabolic syn-
drome. It should be noted that SGLT2 inhibitors
are currently only licenced for use in individuals
with T2DM; their use in T1DM patients is lim-
ited to research studies, or they may be applied
by specialists outside licensed indications.
Small-scale and short-duration studies have
shown that SGLT2 inhibitors can be effective at
reducing HbA1c in T1DM. One study enrolled
75 participants with HbA1c between 58 and
91 mmol/mol and BMI between 18.5 and 35 kg/
m2. Individuals were randomly assigned in a
1:1:1:1 fashion to empagliflozin 2.5 mg, 10 mg,
25 mg or placebo for 28 days in addition to their
standard multiple daily injection (MDI) insulin
regimens [29]. At 28 days there was a significant
difference in HbA1c between those on empa-
gliflozin and the placebo group (a difference
that showed a dose-dependent response).
Another study (albeit single-armed) looked at
the introduction of 25 mg empagliflozin to
standard insulin therapy in 40 participants with
T1DM [30]. The study was intended as a proof of
concept and found a significant reduction in
HbA1c from baseline (8.0 ± 0.9% to
7.6 ± 0.9%; p\ 0.0001), associated with signif-
icant decreases in weight, waist circumference
and total daily insulin dose. Similarly, dapagli-
flozin at 10 mg/day significantly reduced HbA1c
from baseline in 12 overweight patients with
poorly controlled T1DM over a 24-week study
period (9.18 ± 1.02% to 8.05 ± 1.09%;
p = 0.0156) [31]. Sotagliflozin (a dual SGLT1
and SGLT2 inhibitor) also caused a significant
reduction in HbA1c in 33 patients with T1DM
who had an average BMI of 26.6 kg/m2
(- 0.55%, p = 0.002) [32]. Additionally, a recent
RCT involving 1402 patients with an average
HbA1c of 8.26% reported there was a signifi-
cantly greater reduction in HbA1c with sotagli-
flozin compared to placebo after 24 weeks of
treatment (- 0.79%, - 0.33% respectively,
p\0.001) [33].
A recent RCT involving 351 patients on MDI
or CSII insulin therapy trialled the addition of
100 or 300 mg canagliflozin as adjuvant ther-
apy. All patients had T1DM, and the range of
BMI for the group was 21–35 kg/m2. At the
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study endpoint, 18 weeks, those taking cana-
gliflozin at either dose presented a significant
reduction in HbA1c compared to placebo. This
was not accompanied by weight gain in either
group [34]. Other findings of the study were
that there were similar rates of hypoglycaemia
across the groups, and that there was an
increased numerical rate in female genital
mycotic infections in those taking 300 mg
canagliflozin compared to placebo (21.2% vs
5.6%). A further important finding was an
increase in diabetic ketoacidosis (DKA) in those
taking canagliflozin compared to placebo (4.3%,
6.0%, 0% for 100 mg, 300 mg and placebo,
respectively).
An additional recent RCT of 833 patients
with T1DM and poor glycaemic control (HbA1c
61–97 mmol/mol) studied adjuvant dapagli-
flozin at 5 mg/day and 10 mg/day [35]. Adju-
vant dapagliflozin was associated with a
significantly decreased HbA1c versus placebo at
5 mg/day and 10 mg/day (- 0.42%, p\ 0.0001;
- 0.45%, p\ 0.0001, respectively). This effect
was established at week 4 and maintained for
the study duration of 24 weeks. Moreover, a
reduction in body weight of - 2.96%
(p\ 0.001) at 5 mg/day and - 3.72%
(p\ 0.0001) at 10 mg/day was observed. This
effect was established by week 8 and maintained
throughout the study. More genital infections
were reported in the study group compared to
the placebo group (11% for 5 mg/day, 12% for
10 mg/day vs 3% for placebo), but a statistical
analysis was not reported. Similar rates of
hypoglycaemia were observed among the trial
groups. Moreover, there was no statistically
significant difference in definite DKA between
the three study arms (1% for 5 mg/day, 2% for
10 mg/day and 1% for placebo).
Whilst SGLT2 inhibitors are known to reduce
glycaemia, they may also be useful as weight
loss medications. A trial of sotagliflozin, a
combined SGLT1 and SGLT2 inhibitor,
observed a significant reduction in body weight
of 33 patients with an average starting BMI of
26.6 kg/m2 (- 1.7 kg, p\ 0.01) [32]. Similarly,
an RCT involving 1402 patients with an average
baseline BMI of 28.29 kg/m2 reported a signifi-
cant difference in weight loss between the
sotagliflozin and control groups (- 2.98 kg,
p\0.001), with an average loss of 2.21 kg in the
sotagliflozin group and an average weight gain
of 0.77 kg in the control group [32]. Addition-
ally, a trial of 40 patients with various starting
BMIs (18.5–35 kg/m2) identified a 3.5% reduc-
tion in body weight after 8 weeks of 25 mg
empagliflozin, although this was not a placebo-
controlled trial [30]. A trial of 100 mg and
300 mg canagliflozin in patients with BMI
21–35 kg/m2 did show a weight reduction, but
its significance was undetermined (- 3.1% and
- 5.1%, respectively) [34]. Therefore, further
research is required to determine whether the
potent weight-loss effects of SGLT2 inhibitors
observed in patients with T2DM translate to the
T1DM population, as this may highlight a new
target group for these agents [36].
Due to the mechanism of action of SGLT2
inhibitors, hypoglycaemia is not common in
those with T2DM [37]. A meta-analysis of trials
looking at the use of SGLT2 inhibitors in those
with type 1 DM did not find a significantly
different rate of hypoglycaemia compared to
placebo [38].
Changes in insulin requirements have been
reported in some trials investigating the addi-
tion of SGLT2 inhibitors to insulin monother-
apy in type 1 diabetes. One large trial with 1402
participants which studied the addition of
sotagliflozin (a dual SGLT1 and SGLT2 inhi-
bitor) found significant reductions in placebo-
corrected total daily insulin dose, bolus insulin
dose and basal insulin dose (- 9.7%, - 12.3%
and - 9.9%, respectively, p B 0.001 for all) [33].
A recent meta-analysis reported reductions in
both bolus and basal insulin doses when a
SGLT2 inhibitor was added to insulin
monotherapy (- 3.6 units/day, 95% CI - 2.0 to
- 5.3, and - 4.2 units/day, 95% CI - 2.2 to
- 6.3, respectively) [39]. There is therefore good
evidence that adding a SGLT2 inhibitor reduces
the insulin requirement in those with type 1
diabetes, and there appears to be reduction in
both basal and bolus insulin doses for those on
multiple daily injection regimens.
A systematic review and meta-analysis of
trials using SGLT2 inhibitors in addition to
insulin in T1DM found significant improve-
ments in fasting glucose, HbA1c, weight and
total daily insulin dose in those treated with
1836 Diabetes Ther (2018) 9:1831–1851
these medications [38]. However, the systematic
review also highlighted an increased incidence
of diabetic ketoacidosis (DKA) in patients taking
adjuvant SGLT2 inhibitors versus placebo,
identifying 16 cases of DKA in 581 patients. The
review did note that the studies reported both
mild hyperglycaemic and normoglycaemic DKA
as well as typical DKA. Rates of other adverse
events such as hypoglycaemia were not differ-
ent from placebo. This provides evidence that
this drug class is beneficial in those with type 1
diabetes, but the number of trials that met the
search criteria (n = 10) was small. A subsequent
systematic review and meta-analysis including
14 trials published similar results [39]. Signifi-
cant reductions in HbA1c were documented at
0.4% [95% confidence interval (CI) 0.35, 0.46;
p\0.001], as well as significant reductions in
weight, systolic blood pressure, and total daily
insulin dose, accompanied by a reduction in
glucose variability assessed using continuous
glucose monitoring (CGM). Note that the
authors also reported significant increases in
DKA and genital tract infections when com-
pared to placebo (OR 3.38 and 3.44,
respectively).
The EMPA-REG study pointed to a significant
decrease in mortality from cardiovascular causes
in T2DM patients taking empagliflozin com-
pared to placebo [40]. A meta-analysis of studies
looking at cardiovascular outcomes in those
taking SGLT2 inhibitors and suffering from
T2DM highlighted significant reductions in all-
cause mortality as well as mortality from car-
diovascular causes [41]. Direct comparisons
between these study groups of T2DM and T1DM
patients cannot be drawn, but nevertheless, this
drug class shows promising results in reducing
adverse cardiovascular outcomes in those with
impaired glucose metabolism.
In summary, there is early evidence to sup-
port the use of SGLT2 inhibitors as an adjuvant
therapy in patients with T1DM, as there is an
observed reduction in HbA1c without an
increased risk of severe hypoglycaemia. How-
ever, future studies are required with more
comprehensive glycaemic assessment using
continuous glucose monitoring, which will
help to fully establish the glycaemic benefits of
this class of drugs. Moreover, outcome studies
are required to ascertain the role of these drugs
in reducing microvascular and macrovascular
complications in T1DM, as well as to further
answer specific concerns with regards to rates of
DKA and genital tract infections in patients
taking this class of medication.
A summary of the main studies of the use of
SGLT2 inhibitors in T1DM is provided in
Table 2.
GLP-1 RECEPTOR AGONISTS
The key effects of GLP-1 receptor agonists are
that they slow gastric emptying (thus reducing
appetite), enhance pancreatic insulin secretion
and suppress pancreatic glucagon secretion.
These effects work to maintain glucose home-
ostasis in patients with T2DM [42]. Studies
regarding gastric emptying in type 1 diabetes
with GLP-1 analogues are relatively scarce, but
there is some evidence to suggest that this effect
is not observed in this group [43].
Despite the predicted beneficial glycaemic
effects of GLP-1 receptor agonists in T2DM, a
number of recent clinical studies have generally
failed to show an impact of GLP-1 analogues on
HbA1c when used in addition to insulin therapy
in T1DM [44–47]. However, a retrospective
study of exenatide involving a limited number
of patients (n = 11) reported a significant
reduction in HbA1c from baseline (7.7%) to
3 months of treatment (7.1%) (p = 0.013) [48].
Note that all of the patients studied in this ret-
rospective analysis were treated with continu-
ous subcutaneous insulin infusion (CSII). A
6-month trial of exenatide in 13 patients with
HbA1c\ 8.4% found a significant decrease in
postprandial plasma glucose compared to pla-
cebo, suggesting a potential reduction in gly-
caemic variability [47]. Moreover, the bolus
insulin dose was significantly reduced by GLP-1
receptor agonists in a number of studies
[44, 46–48].
Therefore, there is significant interstudy
variability in the results obtained with this class
of drugs in terms of their ability to improve
glycaemic control in T1DM. A meta-analysis of
7 studies (n = 206 participants) has shown a
modest HbA1c reduction caused by the use of
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GLP-1 analogues in T1DM (- 0.21%, p\0.03),
which was associated with a reduction in the
total daily weight-adjusted bolus insulin dose
(- 0.06 l/kg, 95% CI - 0.1 to 0.02, p\0.001),
whereas the total daily insulin was not signifi-
cantly lower than in the placebo group [49].
In general, GLP-1 analogues have shown
promise in their ability to reduce the weight of
T1DM patients. Studies reported weight losses
of between 4.2 and 6.8 kg compared to placebo
over 12–52 weeks in healthy-weight and over-
weight patients [44–48].
A study analysing additional measures of
body fat in overweight patients found a
decrease in waist circumference of 3.3 cm
(p = 0.002) and a decrease in total adipose tissue
(measured by computed tomography) of 61 cm2
compared to placebo (p = 0.0001) [45]. Addi-
tionally, a 6-month retrospective study of exe-
natide in overweight patients with
HbA1c\ 8.4% measured insulin sensitivity
using the hyperinsulinaemic-euglycaemic
clamp method and reported an increase in
insulin sensitivity of 1.94 mg/m2/min per lU/
mL (p = - 0.0039) [47]. A 24-week RCT of
liraglutide in overweight patients with
HbA1c\ 8.5%, however, found no significant
difference in insulin sensitivity [45]. Possible
explanations for this discrepancy in outcome
may be related to differences in study design
and patient population, the limited number of
subjects enrolled, or it may represent a genuine
difference between the two agents studied.
Many trials involving GLP-1 receptor ago-
nists have reported no significant difference in
incidence or rate of hypoglycaemic events
[45, 46, 48], although one study involving 40
overweight T1DM patients has shown a
decrease in hypoglycaemic events (incidence
rate ratio 0.82, 95% CI 0.74–0.90) with GLP-1
analogue therapy [44].
The largest RCTs published on this topic are
the ADJUNCT ONE and ADJUNCT TWO stud-
ies. ADJUNCT ONE recruited 1398 adults with
T1DM to receive liraglutide (at varying doses) or
placebo in a 3:1 randomisation with insulin
being adjusted in a treat-to-target manner over
52 weeks [50]. Despite the treat-to-target design,
there was a numerical decrease in HbA1c across
all three doses of liraglutide at 52 weeks
(0.6 mg/1.2 mg/1.8 mg daily), but only the
reduction seen with the 1.2 mg daily dose was
statistically significant vs placebo (-0.15%, 95%
CI -0.27 to -0.03, p = 0.0164). A statistically
significant reduction in weight was observed
across all liraglutide doses, and total daily
insulin dose was also reduced in the 1.8 and
1.2 mg liraglutide groups vs placebo. Of con-
cern, rates of symptomatic hypoglycaemia were
increased in all liraglutide groups vs placebo,
and there was a significant increase in hyper-
glycaemia with ketosis in those treated with
1.8 mg liraglutide daily in addition to insulin.
ADJUNCT TWO ran for 26 weeks and recruited
835 subjects [51]. Similarly to ADJUNCT ONE,
participants were randomised to liraglutide
0.6 mg/1.2 mg/1.8 mg daily or placebo in a 3:1
manner. In contrast to the aforementioned
study, changes in insulin dosing were capped. A
statistically significant reduction in HbA1c was
observed for all liragutide groups vs placebo,
coupled with reductions in weight and insulin
requirements. However, rates of symptomatic
hypoglycaemia were increased in the liraglutide
1.2 mg group (21.3 vs. 16.6 events/patient/year;
p = 0.03), and rates of hyperglycaemia with
ketosis ([1.5 mmol/L) were increased in those
treated with 1.8 m/day of liraglutide (0.5 vs. 0.1
events/patient/year in liraglutide and placebo
groups, respectively; p = 0.01).
Pancreatitis is a feared consequence of GLP-1
RAs in T2DM. Rates of this event have varied
among studies in T2DM patients, but none of
the studies reviewed for this article reported
pancreatitis as an adverse event. Long-term
follow-up studies will be required to ensure
safety in T1DM.
A summary of the main studies of GLP-1
analogues in T1DM is provided in Table 3.
PRAMLINTIDE
Amylin is a polypeptide co-secreted from pan-
creatic b-cells [52]. Having first been identified
in 1987, there has been a great deal of research
into this hormone and its effects on metabo-
lism, particularly in the first decade of the
twenty-first century. Due to autoimmune
destruction of pancreatic beta cells in type 1
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diabetes, those who suffer with the condition
are rendered unable to produce this hormone in
addition to insulin.
The role of amylin in satiety has become
clearer recently, and it appears to have impor-
tant roles in making the individual ‘‘feel full’’,
thus controlling meal sizes, which may be
partly related to the control of glucagon secre-
tion following food consumption [53, 54]. In
light of this, the role of amylin as adjuvant
therapy in patients with type 1 diabetes has
been explored, particularly in those who are
overweight. An amylin analogue, pramlintide,
is approved for use in the treatment of type 1
and type 2 diabetes in the United States,
although it is not widely used worldwide.
The effect of pramlintide on HbA1c has been
studied in a number of clinical trials involving
patients with type 1 diabetes (Table 4). An early
study found no significant decrease in HbA1c in
those treated with pramlintide vs placebo, but
insulin doses had been reduced prior to com-
mencing therapy, which may have affected the
results [55]. Further studies 26 and 52 weeks in
duration found reductions in HbA1c with
pramlintide vs placebo [56, 57]. A study
52 weeks in duration that included 480 patients
with type 1 diabetes showed a significant
decrease of 0.27% in HbA1c upon comparing
the pramlintide group with the placebo group
[58]. An open-label extension of this study for a
period of 1 year confirmed persistent improve-
ments in HbA1c with continued use. Of note,
the rate of those reaching a target HbA1c
of\7% was also increased in the pramlintide
group.
Due to the pharmacodynamics of pramlin-
tide, it could be expected that a reduction in
weight would be observed in those using it in
conjunction with insulin therapy. Indeed, one
study found a significant decrease in weight
compared to placebo over a 29-week study per-
iod (- 1.3 ± 0.3 kg vs 1.4 ± 0.3 kg;
p =\0.0001) [55], with similar results being
seen over a 26-week study period in another
study (- 1.6 kg placebo-adjusted, p\ 0.001)
[56]. Further work over a 52-week period con-
firmed a decrease in weight with pramlintide
[57]. Another study in adolescents (aged 13–17
years) found significant decreases in weight over
a 4-week period for pramlintide use vs placebo,
indicating that these effects are applicable to a
wide-ranging population [59]. Overall, there is
good evidence that pramlintide reduces weight
in those with type 1 diabetes.
The effects of pramlintide on insulin dosing
have also been extensively evaluated. One study
found a decrease in total daily insulin dose of
12% when pramlintide was used in conjunction
with insulin therapy for 29 weeks. This was
compared to an increase in 1% in those in the
placebo arm of the study, although the signifi-
cance was not reported [55]. A study in adoles-
cents reported a significant decrease in total
daily insulin dose, which was attributed to
decreases in mealtime insulin requirements but
no change in basal insulin dose [59]. A study
52 weeks in duration showed a small increase in
total daily insulin dose in those treated with
pramlintide, but this was significantly lower
than the increase seen in those in the placebo
arm of the trial (2.3% vs 10.3%, p = 0.0176 for
difference between groups) [58].
A decrease in postprandial hyperglycaemia
has been hypothesised as a benefit of the use of
pramlintide therapy in type 1 diabetes. One
study found a decrease in mealtime insulin
requirements in the pramlintide group of 28%
in the first 4 weeks, but this did not alter for the
rest of the study, and basal insulin requirements
were unchanged [57]. This is likely due to a
significant decrease in postprandial glucose in
the pramlintide group as compared to baseline,
which was not observed in the placebo group.
Another study, which assessed the effect of
pramlintide in those using closed-loop insulin
systems, found significant blunting of post-
meal glucose levels and prolongation of time to
maximum glucose level compared to baseline
after 3–4 weeks of pramlintide use [60]. Fur-
thermore, a crossover study involving twelve
patients with type 1 diabetes found a significant
reduction in postprandial hyperglycaemia when
pramlintide was used [61]. Other studies have
confirmed decreases in postprandial glucose
levels [59, 62].
Hypoglycaemia has been evaluated in a
number of studies looking at the adjuvant use of
pramlintide in type 1 diabetes. One study found
no change in overall rates of hypoglycaemia
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compared to placebo, but noted a significant
increase in the rate of severe hypoglycaemia
(event rate/patient year 0.57 ± 0.09 vs
0.30 ± 0.06; p\ 0.05) [55]. Further studies have
not shown increased rates of severe hypogly-
caemia [56, 58, 59]. Additionally, one study
found an increased rate of hypoglycaemia when
commencing pramlintide (first 4 weeks of
study), but this reduced to a rate comparable
with that in the placebo group after this period
[57]. Results are therefore somewhat conflicting,
but on balance it would appear that pramlintide
is not associated with an increased risk of
hypoglycaemia if insulin dosing is adjusted
carefully (as done routinely in clinical trials)
when the patient is started on this medication.
In summary, pramlintide appears to have
positive effects on HbA1c and weight. Effects on
total daily insulin dosing are less clear-cut, but
at worst it does not appear to be inferior to
placebo in this regard. The evidence of a
reduction in postprandial hyperglycaemia in
this class is strong and, with careful adjustment
of the insulin dosing, it does not appear to be
associated with an increased risk of severe
hypoglycaemia.
Of note, the majority of patients with type 1
diabetes are treated with multiple daily injec-
tions of insulin, and the addition of a further
three or four subcutaneous injections daily is
likely a deterrent for many.
DPP-4 INHIBITORS
The use of DPP-4 inhibitors is now widespread
for the treatment of type 2 diabetes, with many
contributory factors leading to their popularity.
Their neutral effect on weight, ease of oral
administration and good tolerability are some
of the factors cited as reasons for high rates of
prescription. However, when investigating their
use in type 1 diabetes, it is apparent that there
are relatively few well-run randomized con-
trolled trials.
A meta-analysis looking at this topic was
published early in 2018 [63]. Only five trials met
the inclusion criteria, which included a total of
253 patients. When one study was excluded due
to a lack of HbA1c data, this glycaemic marker
T
a
b
le
4
co
nt
in
ue
d
W
hi
te
ho
us
e
et
al
.
[5
8]
R
at
ne
r
et
al
.
[5
7]
R
at
ne
r
et
al
.
[5
6]
E
de
lm
an
et
al
.
[5
5]
K
is
hi
ya
m
a
et
al
.
[5
9]
A
dv
er
se
ev
en
ts
re
po
rt
ed
N
au
se
a
an
d
an
or
ex
ia
m
or
e
th
an
tw
of
ol
d
m
or
e
co
m
m
on
in
pr
am
lin
ti
de
gr
ou
p,
bu
t
ef
fe
ct
s
w
er
e
m
ild
.N
o
di
ff
er
en
ce
in
dr
op
ou
t
ra
te
be
tw
ee
n
gr
ou
ps
Si
gn
iﬁ
ca
nt
in
cr
ea
se
in
th
e
ra
te
of
se
ve
re
hy
po
gl
yc
ae
m
ia
in
th
e
ﬁr
st
4
w
ee
ks
of
pr
am
lin
ti
de
us
e.
Fo
llo
w
in
g
th
is
,r
at
es
w
er
e
si
m
ila
r
in
al
l
gr
ou
ps
In
cr
ea
se
d
ra
te
s
of
na
us
ea
,
an
or
ex
ia
an
d
vo
m
it
in
g,
al
th
ou
gh
th
es
e
w
er
e
of
te
n
tr
an
si
en
t
an
d
di
d
no
t
af
fe
ct
pa
rt
ic
ip
an
ts
’d
ai
ly
ac
ti
vi
ti
es
N
o
in
cr
ea
se
in
ri
sk
of
se
ve
re
hy
po
gl
yc
ae
m
ia
re
po
rt
ed
Si
gn
iﬁ
ca
nt
in
cr
ea
se
in
ra
te
of
se
ve
re
hy
po
gl
yc
ae
m
ia
in
pr
am
lin
ti
de
gr
ou
p.
N
o
di
ff
er
en
ce
in
th
e
ra
te
of
no
ns
ev
er
e
hy
po
gl
yc
ae
m
ia
no
te
d
Si
gn
iﬁ
ca
nt
ly
in
cr
ea
se
d
ra
te
s
of
na
us
ea
,v
om
it
in
g
an
d
si
nu
si
ti
s
in
th
e
pr
am
lin
ti
de
gr
ou
p
O
ne
pa
rt
ic
ip
an
t
in
th
e
pr
am
lin
ti
de
gr
ou
p
co
m
pl
ai
ne
d
of
na
us
ea
,
w
hi
ch
re
so
lv
ed
on
al
te
ra
ti
on
of
do
se
,a
nd
th
e
pr
am
lin
ti
de
w
as
su
bs
eq
ue
nt
ly
ti
tr
at
ed
up
ag
ai
n
1846 Diabetes Ther (2018) 9:1831–1851
showed a nonsignificant reduction of - 0.07%
(95% CI: -0.37% to 0.23%).
One study looked at the effects of sitagliptin
on postprandial glucose levels in those with
type 1 diabetes treated with a closed-loop sys-
tem. In this small study, the authors found a
statistically significant decrease in postprandial
glucose when sitagliptin was added, and they
commented that insulin delivery was lower in
the sitagliptin group [64]. No adverse events
were reported by the authors, and there was no
significant difference in the rate of hypogly-
caemia between groups.
Despite the lack of convincing effects of
these agents on HbA1c in type 1 diabetes, there
has been an interest in preserving b-cell func-
tion using these agents [65, 66]. Although early
results are promising, no firm conclusions can
be drawn, and this remains an area for future
research.
CONCLUSION AND FUTURE
PERSPECTIVES
A number of studies have explored the use of
adjuvant therapy in patients with T1DM, but
these have been generally small, of short dura-
tion and have been primarily focussed on gly-
caemia, measured as the change in HbA1c.
There is more to glycaemia than HbA1c, and the
roles of adjuvant therapy in hypoglycaemia,
glucose excursion following meals and gly-
caemic variability are yet to be fully investi-
gated. Also, more attention should be given to
non-glycaemia risk factors such as weight, waist
circumference, blood pressure and insulin
resistance markers. In contrast to T2DM studies,
there is a lack of hard clinical outcome trials
with different therapies in T1DM due to diffi-
culties encountered with the funding of such
work, given the relatively small number of
patients with T1DM and the commercial via-
bility of using adjuvant therapies in those
patients.
Studies so far suggest that adding metformin
to insulin therapy in T1DM temporarily lowers
HbA1c and decreases weight and insulin
requirements, but these effects are not sus-
tained. The side-effect profile is favourable and
the risks associated with this therapy are small.
Therefore, metformin can be added to insulin
therapy in these patients, but only short-term
use is justified given current data. It remains to
be seen whether intermittent treatment with
metformin is superior to long-term use, which
would require carefully designed studies con-
ducted over 3–5 years.
There has been a flurry of research studies
investigating SGLT2 inhibitors in T1DM, and
these agents appear to show the most promise
in correcting hyperglycaemia. Just as for met-
formin, studies investigating the effects of
SGLT2 inhibitors on glycaemic measures other
than HbA1c are generally lacking. Weight and
BP reductions with SGLT2 inhibitors are addi-
tional favourable effects that may prove to
reduce vascular complications and appropriate
outcome studies are needed. In contrast to
metformin, however, there are some safety
concerns primarily related to the precipitation
of DKA, although the incidence of this compli-
cation appears to vary with the agent applied.
GLP-1 agonists may seem like credible partners
to insulin, but studies in T1DM failed to show
sizeable effects of them on glycaemia, although
their role in reducing weight is unquestionable.
There are concerns, based on two large multi-
centre RCTs, that there may be increased rates
of symptomatic hypoglycaemia and hypergly-
caemia with ketosis in those taking liraglutide
with type 1 diabetes, and further investigation
into this is required. Conclusions on the use of
DPP-4 inhibitors in type 1 diabetes are difficult
to draw as there have been few high-quality
clinical trials examining this topic. Pramlintide
has certainly shown positive effects on gly-
caemic control and weight, and does not appear
to have a significant risk profile. The addition of
multiple further injections per day may be a
barrier to its use by many patients with type 1
diabetes, however.
One criticism of adjuvant treatment studies
in T1DM is the assumption that T1DM patients
are a homogeneous group of individuals who
present similar responses to such therapies. It is
likely that adjuvant therapies will work best in a
particular subset of patients, so future studies
should perhaps have a more focussed approach
and concentrate on higher-risk groups. For
Diabetes Ther (2018) 9:1831–1851 1847
example, overweight T1DM patients are known
to have a higher risk of complications, so future
adjuvant studies are needed to investigate this
group of individuals. Also, studies investigating
vascular surrogate markers in the higher-risk
group would be of interest and would help to
decide whether longer-term outcome studies
using adjuvant therapies in T1DM are
warranted.
It is clear that the treatment of T1DM is
evolving, and restricting therapy to insulin
replacement alone is an approach that is too
simplistic. Future longer-term adjuvant studies
on appropriate subgroups of T1DM patients and
investigations of various glycaemic parameters,
surrogate vascular markers and even harder
clinical outcomes will help to refine our
understanding of the role of such therapies in
insulin-deficient states.
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